!""#"$%#& - - PowerPoint PPT Presentation

01 2 0345 6 780 9 08 2 216
SMART_READER_LITE
LIVE PREVIEW

!""#"$%#& - - PowerPoint PPT Presentation

!""#"$%#& *+,-,.&,/(01&-+*2&,*0345*6&780&9:08+*(2&'(;*216& '()*&%& From strategies to services eHealth as the enabler for cross- border healthcare From Strategies to Services


slide-1
SLIDE 1

!""#"$%#& '()*&%& *+,-,.&,/(01&-+*2&,*0345*6&780&9:08+*(2&'(;*216&

slide-2
SLIDE 2

From strategies to services – eHealth as the enabler for cross- border healthcare

slide-3
SLIDE 3

From Strategies to Services

  • !

Provide concrete cross border services that ensure safe, secure and efficient medical treatment for citizens when travelling across Europe

  • !

Focus on services close to the patient: –! Patient Summary for EU Citizens

  • ! Occasional Visit
  • ! Regular Visit

–! ePrescribing for EU Citizens

  • ! Medication Re-dispense
  • ! Medication Occasional Dispense
  • !

Build on existing National eHealth Projects and use experiences and knowledge from all Member States

slide-4
SLIDE 4
  • ! Healthcare a strict national prerogative
  • ! Previously only limited co-operation on a general policy level
  • ! Substantial variations between national healthcare systems, but

also similar challenges are faced and….

  • ! …substantial similarities in political ambitions to reform

healthcare as well as in the challenges to reach these goals

  • ! The work started in 2003-2006 at the Ministerial Conferences
  • ! In 2004 the eHealth Action Plan was adopted and the I2010 was

created

  • ! And in 2007 in Berlin the eHealth Initiative was created.…

Closer Cooperation on Healthcare

slide-5
SLIDE 5

a new era in legal and policy framework for EU Cooperation on eHealth

  • ! Proposal for a European Directive on patients’ rights in cross-

border healthcare

  • ! Commission Recommendation on cross-border interoperability of

electronic health record systems

  • ! Communication on telemedicine for the benefit of patients,

healthcare systems and society

  • ! eHealth Standardisation Mandate 403

2008 a New Era

slide-6
SLIDE 6
  • ! Goal for the epSOS eHealth Project:

–! “to develop a practical eHealth framework and ICT infrastructure that will enable secure access to patient health information, particularly with respect to a basic patient summary and ePrescription, between European healthcare systems”

  • ! Challenges to get there:

–! Legal Interoperability –! Organisational Interoperability –! Semantic Interoperability –! Technical Interoperability

Goals & Challenges

slide-7
SLIDE 7

<=*&'08>*51&<*(/&58264616&87&!?&@*2*A54(04*6&708/&%!& /*/@*0&61(1*6B&!"#$%&#$'(#$')#$(*#$(+#$,-#$."#$/*#$+)#$ +($012$345$6)$& –!#&C(;82(D&E4246104*6&87&F*(D1=G%H&C(;82(DI 0*)482(D&J8/+*1*25*&J*21*06K&$ –!J8/+*1*25*&J*21*06&L25D:M42)IN80O42)&N41=&D85(D& 80)(24P(;826&N41=&1=8:6(2M6&87&J82104@:1806& –!LF9.9:08+*&0*+0*6*2;2)&LJ<&42M:610Q&1*(/&

The Pilot Team

slide-8
SLIDE 8

The Industry team

78$ !99513:;5$$ !<=0$>50?34%0;5$$ !@A??A$ B;CDE4$"5?59AF$$ %CE9A$$ %8G$852C90$$ %:E3A2CH$$ 2I8ADA1$$ '520?:E$$ (?593;A1C9$-59A;2$%AF@01J$$ (".!8$$ K($>50?3490;5$$ K1AFA1$$ .%L$$ .12;0$ .1=A153$$ .1EC5?$$ .135?$%A;@A;0DA1$+M!M$$ *AFI0;2C0$.1=A;F0D90$$ 8C9;AEAN$$ /53EF0;3$$ O;09?5$$ GAE0F$$

  • .+($$

+C15:;0$+@!$$ +F0;3.+$$ +35;C0$8:FF5;3$%A1E:?D1<$!K$$ "C01CP+@C;C3$$ ";5I?58$ "P+JE35FE$ QP351DA1$

slide-9
SLIDE 9

EU memberstate (not participating) Non EU country Single (national) patient identifier Multiple (regional) patient identifiers

Availability of Patient identifier 2008

slide-10
SLIDE 10

EU memberstate (not participating) Non EU country Single (national) patient identifier Multiple (regional) patient identifiers

Availability of Patient Identifier 2010

slide-11
SLIDE 11

Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available

HCP/HCPO Identifier – Suitability for Authentication & Digital signing 2008

slide-12
SLIDE 12

Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available

HCP/HCPO Identifier – Suitability for Authentication & Digital signing 2010

slide-13
SLIDE 13

Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available

Availability of opt-out Consent 2008

slide-14
SLIDE 14

Nationally-led Regionally-led Not available / unknown EU memberstate (not participating) Non EU country Fully available Partly available Fully available Partly available Opt-out likely to be implemented

Availability of opt-out consent 2010

slide-15
SLIDE 15

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of Patient Summary 2008

slide-16
SLIDE 16

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of Patient Summary 2010

slide-17
SLIDE 17

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of ePrescriptions 2008

slide-18
SLIDE 18

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of ePrescriptions 2010

slide-19
SLIDE 19

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of Dispense Information 2008

slide-20
SLIDE 20

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of Dispense Information 2010

slide-21
SLIDE 21

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of Medication Summary 2008

slide-22
SLIDE 22

Nationally available & operational Regionally available & operational Not available / unknown EU memberstate (not participating) Non EU country >25% <25% >25% <25%

Availability of Medication Summary 2010

slide-23
SLIDE 23

LC34A:3$0R5F@D1<$3A$C135;S515$C1$345$ 5HCED1<$$8+$?5<0?$=;0F5TA;UEM$!1$ V5@+O+$?5<0?$C135;A@5;0IC?C3J$?0J5;W$ CE$9;50352M$ XM! @;ASCECA1E$=A;$022;5EEC1<$0??$ 5EE51D0?$*Y-$;5Z:C;5F513E$A=$ 8+$0E$@0;3$A=$345$25EC<1$[$$ \M! E:94$@;ASCECA1E$0;5$3;01E?0352$ C13A$EJE35F$012$E5;SC95$ E@59C]90DA1E$^E0=5<:0;2E_$ 7M! !@@?C90DA1$A=$E0=5<:0;2E$CE$ 0:2C30I?5$`$)5J$-A?5$A=$/%GE$

Legal Interoperability

slide-24
SLIDE 24

80C1$.EE:5E$ *5<0?$ %5;30C13J$ 5@+O+$ !@@;A094$ 80C1$%40??51<5$ (H@59352$.F@093$

'030$G;A359DA1$ 012$%A1]251D0?C3J$

+:a9C513$ =525;0D1<$ 10DA10?$3;:E3$ EJE35FE$ (6$?5S5?$.1=A;F0DA1$ KAS5;10195$ 3AT0;2E$ 40;FA1Cb0DA1$A=$ @;09D95$

>50?34$+JE35FE$

*AT$ 5@+O+$ @A?C9C5E$012$ E0=5<:0;2E$ E59:;5$9A??0IA;0DA1$ TC34$?A90?$0:34A;CD5E$ "AT0;2E$0995?5;0D1<$ 345$25@?AJF513$A=$ ;5CFI:;E0I?5$5>50?34$ 9;AEE$IA;25;$E5;SC95E$

G;A=5EECA10?$ 0E@593E$012$EA9C0?$ 9A135H3$$

*AT$ 9A:13;J$A=$ 3;503F513$ ;:?5E$0@@?J$ (H@?A;5$@;A=5EECA10?$ ;C<43E$C1$345$9A135H3$A=$ 9;AEE$IA;25;$90;5$ "AT0;2E$?5<0?$ 95;30C13J$A1$ @;A=5EECA10?E$;C<43E$C1$ 345$I;A025;$9A135H3$ 5M<M$$35?5F52C9C15$

*C0IC?C3J$

*AT$ 5?0IA;0DA1$ A=$E@59C]9$ E0=5<:0;2E$$ 9A??0IA;0DA1$TC34$(6$ ?5S5?$@;A=5EECA10?$ 0EEA9C0DA1E#$012$ E30U54A?25;E$ "AT0;2E$F:3:0?$ ;59A<1CDA1$

Legal Issues: Summary of findings

slide-25
SLIDE 25

<=*&R*D43*0*M& –! L24;(D&,58+*& –! S*)(D&T&U*):D(180Q&J82610(4216& –! U*+801&82&-++801:24;*6&(2M&J82610(4216&87&+(0;54+(;2)&E,& –! R466*/42(;82&J825*+1&(2M&'D(2& –! 93(D:(;82&E*1=8M8D8)Q&(2M&'D(2& –! U*346*M&'08>*51&'D(2& –! R0(V&R*A24;82&87&8+*0(;82(D&,*0345*&U*W:40*/*216.& *'0*6504+;82& –! R0(V&R*A24;82&87&8+*0(;82(D&,*0345*&U*W:40*/*216&X& '(;*21&,://(0Q&

Where are we at?

slide-26
SLIDE 26

<=*&R*D43*0(@D*6&18&@*&R*D43*0*M&(1&1=*&*2M&87&1=*&Q*(0&18&1=*& J8//466482$& –! ,*5:041Q&6*0345*6&6+*54A5(;82&M*A24;82& –! LM*2;1Q&/(2()*/*21&6*0345*6&6+*54A5(;82&M*A24;82& –! R0(V&*+,-,&6Q61*/&1*5=245(D&6+*54A5(;82& –! ,*/(2;5&,*0345*6&M*A24;82& –! J8//82&J8/+82*216&,+*54A5(;82& –! <*61&,5*2(0486&(2M&,41*&J=845*& –! R0(V&C(;82(D&'4D81&,*1:+&(2M&R*+D8Q/*21&):4M*& –! L21*08+*0(@4D41Q&70(/*N80O& –! ,1(2M(0M&J8210(516&1*0/6&780&E,&M85:/*21&780&*2)()*/*21& 87&+4D816&

What is next?

slide-27
SLIDE 27

Overall Project Plan

  • !

Asking for approval of D5.2.2 Revised Project plan:

  • ! Conclusion after analysis and re-planning: Extension of project duration by 6

months

slide-28
SLIDE 28

<=*&'08>*51&<*(/&58264616&87&!?&@*2*A54(04*6&708/&%!& /*/@*0&61(1*6B&!"#$%&#$'(#$')#$(*#$(+#$,-#$."#$/*#$+)#$ +($012$345$6)$& F(3*&780/(DDQ&(6O*M&18&>842& –!961824(& –!Y42D(2M& –!L5*D(2M& –!,D83*24(& –!'801:)(D&

F(3*&>842*M&J(DD48+*&

–!C80N(Q&& –!,N41P*0D(2M&

Where are we at?

slide-29
SLIDE 29
  • ! J8//:245(;82&N41=&(&@08(M*0&(:M4*25*&42&@81=&M40*5;826&&
  • ! L270(610:51:0*&780&M466*/42(;82&(5;34;*6&&
  • ! Z:(D4A*M&7**M@(5O&&
  • ! L2+:1&708/&J(DD48+*[6&M*A2*M&(0*(6&87&N80O&\U8(M/(+G&9].

0*58//*2M(;826G&,1(2M(0M6^&

http://www.calliope-network.eu/

slide-30
SLIDE 30

Mikael Erlandsson

Cooperation is Necessary

slide-31
SLIDE 31

!""""$"$& _%& *+,-,&X&,/(01&-+*2&,*0345*6&780&9:08+*(2&'(;*216&

Thank you for your attention! www.epsos.eu